SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Fusion Pharmaceuticals Inc. (FUSN) .
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($15.25, 29.2%).
- 分析师共识目标价 $15.25 (-29.2% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 30/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
估值概览 — FUSN
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率683.72
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.45
每股账面价值$0.00
每股营收$0.03
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$15.25 (-29.2%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2017 |
$-0.34 |
$0.00 |
$-6.26M |
- |
| 2018 |
$-0.62 |
$0.00 |
$-11.65M |
- |
| 2019 |
$-0.10 |
$0.00 |
$-16.19M |
- |
| 2020 |
$-3.56 |
$0.00 |
$-78.33M |
- |
| 2021 |
$-1.90 |
$1.44M |
$-81.05M |
-5628.3% |
| 2022 |
$-2.00 |
$1.46M |
$-87.61M |
-5996.7% |
| 2023 |
$-1.45 |
$2.07M |
$-94.9M |
-4588.8% |
